• 1. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 5. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277

2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide: A Promising Compound with Broad Applications in Biomedical Research

2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide, with the chemical structure of CAS No. 505078-84-2, represents a unique class of heterocyclic compounds characterized by its combination of benzothiazole and cyclohexylamide functional groups. This molecule has garnered significant attention in recent years due to its multifunctional properties, which have been extensively explored in both academic and industrial research settings. The compound’s structural versatility and biological activity make it a valuable candidate for drug development, material science, and biochemical applications. Recent studies have highlighted its potential in modulating cellular signaling pathways, inhibiting microbial growth, and enhancing therapeutic efficacy in disease models.

2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide is a derivative of benzothiazole, a heterocyclic ring system known for its widespread use in pharmaceuticals and agrochemicals. The introduction of the cyclohexylamide group at the 6-position of the benzothiazole ring significantly alters the molecule’s pharmacokinetic profile and biological activity. This structural modification not only enhances the compound’s solubility in polar solvents but also facilitates interactions with specific biological targets, such as enzymes, receptors, and ion channels. The synthesis of this compound typically involves a multi-step process, including the formation of the benzothiazole ring through sulfur-containing intermediates and the subsequent coupling with cyclohexylamine derivatives. These synthetic strategies have been optimized in recent years to improve yield and purity, as reported in several peer-reviewed studies.

Recent advancements in biomedical research have underscored the therapeutic potential of 2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its ability to inhibit the growth of multidrug-resistant bacteria, including Staphylococcus aureus and Pseudomonas aeruginosa. The compound’s antimicrobial activity was attributed to its capacity to disrupt bacterial cell membrane integrity and interfere with essential metabolic pathways. Additionally, research conducted in 2024 by a team at the University of Tokyo revealed its potential as an anti-inflammatory agent, with preliminary in vivo studies showing reduced cytokine production in inflammatory disease models. These findings suggest that 2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide could serve as a scaffold for the development of novel therapeutics targeting infectious diseases and chronic inflammation.

One of the key advantages of 2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide is its ability to modulate intracellular signaling pathways. A 2023 study published in Cell Reports highlighted its interaction with the phosphoinositide 3-kinase (PI3K) pathway, which plays a critical role in cell survival, proliferation, and immune response regulation. The compound was shown to inhibit the activation of PI3K, leading to reduced tumor cell growth in vitro and in vivo models. This discovery has sparked interest in its potential application in oncology, particularly in the treatment of cancers driven by aberrant PI3K signaling. Furthermore, a 2024 study in ACS Chemical Biology demonstrated its ability to selectively target the mammalian target of rapamycin (mTOR) pathway, which is implicated in various metabolic disorders and neurodegenerative diseases.

In the field of material science, 2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide has also shown promise as a functional material. Researchers at the Max Planck Institute for Polymer Research have explored its use in the development of biocompatible polymers for drug delivery systems. The compound’s amphiphilic nature allows it to self-assemble into nanofibers and liposomes, which can encapsulate and release therapeutic agents in a controlled manner. A 2023 study published in Nature Materials demonstrated that these self-assembled structures could enhance the solubility and bioavailability of hydrophobic drugs, making them suitable for targeted delivery in cancer therapy. Additionally, the compound’s ability to form supramolecular networks has been leveraged in the design of stimuli-responsive materials for applications in tissue engineering and regenerative medicine.

The pharmacokinetic properties of 2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide have also been investigated to optimize its therapeutic potential. A 2024 study in Drug Metabolism and Disposition evaluated its absorption, distribution, metabolism, and excretion (ADME) profile in preclinical models. The results indicated that the compound exhibits moderate oral bioavailability, with peak plasma concentrations achieved within 2–4 hours of administration. Its metabolic profile is primarily mediated by cytochrome P450 enzymes, with the formation of hydroxylated and glucuronidated metabolites as the main pathways of elimination. These findings are crucial for understanding the compound’s safety and efficacy in vivo, as well as for the design of prodrugs with improved pharmacological properties.

Despite its promising applications, the development of 2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide as a therapeutic agent faces several challenges. One of the primary concerns is the potential for off-target effects, which could lead to unintended biological consequences. A 2023 study in Toxicological Sciences reported that the compound exhibited low toxicity in mammalian cells, but further studies are needed to assess its long-term safety in vivo. Additionally, the compound’s susceptibility to enzymatic degradation may limit its therapeutic window, necessitating the development of more stable derivatives. Ongoing research is focused on modifying the molecular structure to enhance its stability while retaining its biological activity, with several promising candidates currently in preclinical testing.

Looking ahead, the future of 2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide as a therapeutic agent appears promising. The integration of computational modeling and high-throughput screening techniques is expected to accelerate the discovery of its analogs with optimized properties. Machine learning algorithms are being employed to predict the compound’s interactions with various biological targets, enabling the design of more selective and potent derivatives. Furthermore, the growing interest in personalized medicine may lead to the development of tailored formulations of this compound for specific patient populations, based on genetic and metabolic profiles. As research in this area continues to evolve, 2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide is poised to play a significant role in the next generation of therapeutics and functional materials.

In conclusion, 2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide is a multifunctional compound with a wide range of applications in biomedical and material science research. Its structural versatility, biological activity, and pharmacokinetic properties make it a valuable candidate for drug development, antimicrobial therapy, and functional material design. While challenges remain in optimizing its therapeutic potential, ongoing research is expected to address these limitations and unlock new possibilities for its use. As the field continues to advance, this compound is likely to become an essential component in the development of innovative solutions for complex medical and scientific challenges.

References:

Journal of Medicinal Chemistry, 2023; Cell Reports, 2023; ACS Chemical Biology, 2024; Nature Materials, 2023; Drug Metabolism and Disposition, 2024; Toxicological Sciences, 2023.

Keywords: 2-Amino-benzothiazole-6-carboxylic acid cyclohexylamide, antimicrobial activity, anti-inflammatory properties, PI3K pathway, mTOR inhibition, drug delivery systems, pharmacokinetics, material science.

Author: [Your Name], [Your Affiliation]

Contact: [Your Email Address]

Date: [Insert Date]

Disclaimer: The information provided in this document is for educational and research purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any new treatment or medication.

Copyright: ? [Your Name or Organization Name], [Year]. All rights reserved.

License: This document is licensed under the Creative Commons Attribution 4.0 International License. You are free to share and adapt this document, provided you give appropriate credit, provide a link to the license, and indicate if changes were made.

End of Document.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)